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Identity 
Other names: CBP35, GAL3, GALBP, GALIG, L31, 
LGALS2, MAC2 




Size 16277 bases. 
Consists of at least 6 exons. 
Transcription 
Two transcription initiation sites were identified in
human LGALS3. These transcripts arise from an 
internal gene embedded within LGALS3, named galig 
(galectin-3 internal gene) (Barondes et al., 1994; 





250 amino acids; 26152 Da; The initial 12 amino acid 
N-terminal peptide sequence also called small N-
terminal, precede the proline/glycin-rich repetitive 
domain consisting of about 100 amino acids. C-
terminal consists of about 130 amino acids encoding 
carbohydrate-binding domain. Galectin-3 is the only 
chimeric protein among a family of 15 galectins know  
so far (Hirayabashi and Kasai, 1998). 
Localisation 
In adults, galectin-3 is ubiquitously expressed and 
localizes to the extracellular matrix, the cytoplasm and 
the nucleus (Hirayabashi and Kasai, 1998; Krzeslak 
and Lipinska, 2004). 
Function 
Galectin-3 is a carbohydrate-binding protein: a 
characteristic that it shares with other members of 
galectin family. The collagen alpha like N terminal 
sequence can be cleaved by Matrix metalloproteinases 
and the cleavage results in an enhanced binding 
efficiency to carbohydrates (Ochieng et al., 1994; 
Shekhar et al., 2004). Intra-cellularly it functions as an 
anti-apototic protein because of the presence of Asp-
Trp-Gly-Arg (NWGR) motif at the C terminal 
(Akahani et al., 1997; Nakahara et al., 2005; Yang et 
al., 1996). NWGR is designated as the anti-death motif 
characteristic of the BCL2 family. Extra-cellular 
protein however, functions as a pro-apoptotic entity on 
T cells (Fukumori et al., 2003). Galectin-3 has also 
exhibited pro-angiogenic properties (Nangia-Makker et 
al., 2000). 
Homology 
N-terminal domain has 33.5% identity with collagen 
alpha1 (II) chain of bovine cartilage, so it is also 
designated as a collagen-like N-terminal domain. The 
C-terminal domain of galectin-3, forming a globular 
structure, accommodates whole carbohydrate-binding 
site, and is very similar to CRD of other lectins. 
Mutations 
Germinal 
P64H (rs4644), T98P (rs4652), R183K (rs10148371). 
Functional germline mutation in the galectin-3 gene at 
position 191 (rs4644) substituting proline with histidine 
(P64H), which results in susceptibility to matrix 
metalloproteinase cleavage and acquisition of 
resistance to drug-induced apoptosis. This substitution 
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correlates with incidence of breast cancer and racial 
disparity (Balan et al., 2008). Rs10148371 is localized 






Over-expression of galectin-3 was reported in the 
metastatic cell lines compared to their non-metastaic 
counterparts. Galectin-3 concentrations were 
significantly higher in the serum of patients with 
melanoma and breast cancer compared to the normal 
controls. In the tumor tissues, upregulation and/or 
redistribution of galectin-3 was shown in thyroid, 
colon, breast, gastric, prostate, melanoma and headand 
neck cancers, however, the data in some cases are not 
consistent (Dumic et al., 2006; Yang et al., 2008). 
Recently, it was reported in breast and prostate cancer 
that after cleavage by Matrix metalloproteases galectin-
3 is not recognized by the commonly used monoclonal 
antibody TIB166 (Nangia-Makker et al., 2007; Wang et 
al., 2009), which could explain some of the discrepancy 
in the earlier reports. 
Autoimmune disease 
Disease 
Galectin-3 plays a role in pathogenesis of autoimmune 
disease. Endogenous protein promotes inflammatory 
response in asthma, pharmacological application of 
galectin-3 might suppress it (del Pozo et al., 2002; 
Zuberi et al., 2004), thus opening a new approach for 
future treatment of the disease. In Crohn's disease and 
systemic lupus, erythematosus and 
polymyositis/dermatomyositis anti-galectin-3 auto-
antibodies were identified (Jensen-Jarolim et al., 2001; 
Lim et al., 2002). In sera and synovial fluid from 
rheumatoid arthritis (RA) patients, galectin-3 level was 
found to be elevated (Ohshima et al., 2003). 
Prognosis 
Galectin-3 is differentially expressed in thyroid 
carcinoma compared with benign and normal thyroid 
specimens, suggesting that Galectin-3 is a good 
diagnostic marker for thyroid cancer (Chiu et al., 
2010). 
Oncogenesis 
Galectin-3 is not an oncogene, but helps in cancer 
progression once it is initiated. 
To be noted 
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